Anti-Fibrinolytic Drugs - Iraq

Iraq

The Anti-Fibrinolytic Drugs market in Iraq is expected to witness a significant growth in revenue, with projections indicating a reach of US$19.62m by the year 2024.
Furthermore, it is anticipated that the market will exhibit a steady annual growth rate (CAGR 2024-2029) of 4.95%, leading to a market volume of US$24.98m by 2029.
In terms of global comparison, United States is predicted to generate the highest revenue in the market, with an estimated US$9,858.00m in the year 2024.
Iraq is experiencing a growing demand for anti-fibrinolytic drugs due to an increasing prevalence of conditions requiring hemostasis management.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The use of Anti-Fibrinolytic Drugs in Iraq has been on an upward trend in recent years.

Customer preferences: Iraq has a high incidence of bleeding disorders such as hemophilia and thrombocytopenia, which has led to an increasing demand for Anti-Fibrinolytic Drugs. Additionally, the country has seen a rise in trauma cases due to ongoing conflicts, leading to an increased need for drugs that can help control bleeding.

Trends in the market: The Anti-Fibrinolytic Drugs market in Iraq has been growing steadily due to an increase in demand. With the rise in trauma cases, healthcare providers have been prescribing more Anti-Fibrinolytic Drugs to help control bleeding. Additionally, the availability of these drugs has improved in recent years, making them more accessible to patients.

Local special circumstances: Iraq has been experiencing ongoing conflicts, which has led to a strain on the healthcare system. This has made it difficult for patients to access healthcare services, including the necessary drugs. However, efforts have been made to improve the availability of drugs, including Anti-Fibrinolytic Drugs, through the establishment of mobile clinics and the distribution of drugs to remote areas.

Underlying macroeconomic factors: The Iraqi economy has been struggling in recent years due to a number of factors, including ongoing conflicts and a drop in oil prices. This has led to a decrease in government spending on healthcare, which has put a strain on the healthcare system. However, efforts have been made to improve the healthcare system, including the establishment of new hospitals and the training of healthcare professionals. This has helped to improve the availability of drugs, including Anti-Fibrinolytic Drugs, to patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.